2010
DOI: 10.1183/09031936.00195609
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Median survival of patients with brain metastases from nonsmall cell lung cancer (NSCLC) is poor and more effective treatments are urgently needed. We have evaluated the efficacy of erlotinib in this setting and its association with activating mutations in the epidermal growth factor receptor (EGFR) gene.We retrospectively identified patients with NSCLC and brain metastases treated with erlotinib. EGFR mutations in exons 19 and 21 were analysed by direct sequencing. Efficacy and tolerability were compared acco… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

5
163
1
2

Year Published

2011
2011
2020
2020

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 280 publications
(171 citation statements)
references
References 27 publications
(35 reference statements)
5
163
1
2
Order By: Relevance
“…However, in patients with EGFR mutations, the rate was increased to 70-80%. The rate was found to be higher in patients with wild-type EGFR (8,9). Those results were consistent with the curative effect of erlotinib treating extracranial lesions in patients with EGFR mutations and non-small-cell lung cancer (5).…”
Section: Discussionsupporting
confidence: 77%
See 3 more Smart Citations
“…However, in patients with EGFR mutations, the rate was increased to 70-80%. The rate was found to be higher in patients with wild-type EGFR (8,9). Those results were consistent with the curative effect of erlotinib treating extracranial lesions in patients with EGFR mutations and non-small-cell lung cancer (5).…”
Section: Discussionsupporting
confidence: 77%
“…For this group of patients, the median survival rate was reported to be 12-16 months. Thus, this type of treatment may be an effective option for non-small-cell lung cancer with brain metastases (8,9). However, the main failure pattern of this type of treatment is in the progression of intracranial lesions.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…There have been few reported cases of responses to brain metastases in NSCLC in patients receiving erlotinib by 2008 [15][16][17] . A recent retrospective study [25] claimed that erlotinib is active in BM from NSCLC and the clinical benefit is related to the presence of activating mutations in Exon 19 or 20 of EGFR gene. In this study, EGFR status was not assessed in most of patients, 105 patients received 1-33 months TKIs after systemic chemotherapy or brain irradiation, 35 patients received only 1-3 months administration of TKIs because of ineffectiveness, and 70 patients received more than 3 months TKIs with 21 months of MST.…”
Section: Multiple Modalities and Overall Survivalmentioning
confidence: 99%